Phaseline

Companies › CSPC ZhongQi Pharmaceutical Technology

CSPC ZhongQi Pharmaceutical Technology: clinical trials, targets and expected readouts

16 active drug programs in 118 registered trials: 58 Phase 2, 44 Phase 1, 13 Phase 3, 3 Phase 4; Oncology, Gastroenterology, Other, Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DP303c
Antibody-drug conjugate (ADC)
–Phase 3HER2-positive Breast Cancer; Advanced Solid TumorsOct 2027
Mitoxantrone
DNA topoisomerase II alpha inhibitor
TOP2APhase 3Peripheral T Cell Lymphoma; Acute Myeloid Leukaemia; B-cell Acute Lymphoblastic Leukemia; Soft Tissue Sarcoma …Dec 2027
Glumetinib
MEK inhibitor
MAP2K1Phase 2Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsApr 2027
CM326
Unclear - not stated in registry
–Phase 2Chronic Obstructive Pulmonary DiseaseJul 2027
SYHX2008 injection
Somatostatin somatostatin receptor 2 (SSTR2) agonist
–Phase 2Gastrointestinal Neuroendocrine Pancreatic TumorAug 2027
Sirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 2HR+/HER2- Advanced/Metastatic Breast Cancer; Gastroenteropancreatic Neuroendocrine Tumors; Advanced Solid Tumors; Antiphospholipid (aPL)-Positive …Oct 2027
Octreotide
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 2Gastroenteropancreatic Neuroendocrine Tumors; Pancreas Head CancerAug 2028
CM310
Recombinant humanized monoclonal antibody
–Phase 2Moderate to Severe AsthmaMay 2032
Ammoxetine hydrochloride Enteric-coated Tablets (new formulation)
norepinephrine-dopamine reuptake inhibitor
SLC6A3Phase 1Healthy ParticipantsNov 2026
SYH2085–Phase 1Healthy ParticipantsNov 2026
SKLB1028–Phase 1Newly Diagnosed Acute Myeloid Leukemia (AML)Dec 2026
SYH2082 Injection–Phase 1Overweight or ObesityJan 2027
SYS6002
Antibody-drug conjugate (ADC)
–Phase 1Advanced Solid TumorsOct 2027
SYS6010
Antibody-drug conjugate (ADC)
–Phase 1Advanced Solid TumorsOct 2027
SYS6043
Antibody-drug conjugate (ADC)
–Phase 1Advanced Solid TumorsOct 2027
SYS6020 injection
Autologous CAR-T cells transfected with LNP-mRNA targeting BCMA
–Phase 1Myasthenia GravisDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05299164MitoxantronePhase 1Non Hodgkin LymphomaOncologyDec 2023
NCT05299164MitoxantronePhase 1Non Hodgkin LymphomaOncologyDec 2023
NCT05299164MitoxantronePhase 1Non Hodgkin LymphomaOncologyDec 2023
NCT05299164MitoxantronePhase 1Non Hodgkin LymphomaOncologyDec 2023
NCT06220097MitoxantronePhase 2B-cell Acute Lymphoblastic LeukemiaOncologyAug 2024
NCT04582136SirolimusPhase 3Systemic Lupus ErythematosusImmunologyApr 2025
NCT05464433MitoxantronePhase 1Extranodal Natural Killer T Cell LymphomaOncologyApr 2025
NCT06957379SirolimusPhase 2HR+/HER2- Advanced/Metastatic Breast CancerOncologyJun 2025
NCT03150914SirolimusPhase 3LAMInfectious diseaseJun 2025
NCT05836025SirolimusPhase 2PerimenopausalGenitourinaryOct 2025
NCT02574728SirolimusPhase 2CancerOncologyJun 2026
NCT01087554SirolimusPhase 1Advanced CancerOncologyAug 2026
NCT07756996Ammoxetine hydrochloride Enteric-coated Tablets (new formulation)Phase 1Healthy ParticipantsOtherAug 2026
NCT04742777SirolimusPhase 2AgingOtherOct 2026
NCT07694869Ammoxetine hydrochloride Enteric-coated Tablets (new formulation)Phase 1Healthy ParticipantsGenitourinaryNov 2026
NCT07412353SYH2085Phase 1Healthy ParticipantsOtherNov 2026
NCT07694843Ammoxetine hydrochloride Enteric-coated Tablets (new formulation)Phase 1Healthy ParticipantsGastroenterologyNov 2026
NCT06246162MitoxantronePhase 1Multiple MyelomaOncologyNov 2026
NCT05384756SirolimusPhase 1Sickle Cell DiseaseHematologyDec 2026
NCT06514313MitoxantronePhase 2Soft Tissue SarcomaOncologyDec 2026
NCT04948203SirolimusPhase 2Pulmonary FibrosisRespiratoryDec 2026
NCT03099356SirolimusPhase 2Metastatic Thyroid CancerOncologyDec 2026
NCT03258320MitoxantronePhase 2Prostate Cancer PatientsOncologyDec 2026
NCT06429449MitoxantronePhase 1LeukemiaOncologyDec 2026
NCT06673290SirolimusPhase 2Lymphatic MalformationOtherDec 2026
NCT05958719MitoxantronePhase 2Peripheral T Cell LymphomaOncologyDec 2026
NCT03901001SirolimusPhase 3InfluenzaInfectious diseaseDec 2026
NCT06960928SirolimusPhase 3Long COVID-19Infectious diseaseDec 2026
NCT06091332SirolimusPhase 2Cavernous MalformationsNeurologyDec 2026
NCT05426252SirolimusPhase 1Thalassemia in ChildrenHematologyDec 2026
NCT06345365MitoxantronePhase 3Acute Myeloid LeukaemiaOncologyDec 2026
NCT06621212MitoxantronePhase 2Relapsed/Refractory Acute Myeloid LeukaemiaOncologyDec 2026
NCT06651866MitoxantronePhase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT05445154SKLB1028Phase 1Newly Diagnosed Acute Myeloid Leukemia (AML)OncologyDec 2026
NCT04375813SirolimusPhase 2Non-muscle Invasive Bladder CancerOncologyJan 2027
NCT06802055SirolimusPhase 2Aplastic AnaemiaHematologyJan 2027
NCT07532655SYH2082 InjectionPhase 1Overweight or ObesityMetabolic and endocrineJan 2027
NCT03243019SirolimusPhase 2Lymphatic MalformationOtherFeb 2027
NCT04375631MitoxantronePhase 1Recurrent Acute Myeloid LeukemiaOncologyFeb 2027
NCT04629495SirolimusPhase 2Mild Cognitive ImpairmentNeurologyMar 2027
NCT05949658SirolimusPhase 1AgingOtherMar 2027
NCT04959175SirolimusPhase 1Hematologic NeoplasmsOncologyApr 2027
NCT06947291GlumetinibPhase 2Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsOncologyApr 2027
NCT03192397SirolimusPhase 1Acute Myeloid Leukemia in RemissionOncologyMay 2027
NCT05036226SirolimusPhase 1Prostate Cancer RecurrentOncologyMay 2027
NCT06447090MitoxantronePhase 2Relapse Acute Myeloid LeukemiaOncologyMay 2027
NCT06447090MitoxantronePhase 2Relapse Acute Myeloid LeukemiaOncologyMay 2027
NCT07058974SirolimusPhase 1SmokersOtherJun 2027
NCT05436418SirolimusPhase 1Peripheral Blood Stem Cell TransplantationOncologyJun 2027
NCT05104983SirolimusPhase 2Tuberous Sclerosis ComplexNeurologyJun 2027
NCT07418736CM326Phase 2Chronic Obstructive Pulmonary DiseaseRespiratoryJul 2027
NCT06594640MitoxantronePhase 1Diffuse Large B-cell LymphomaOncologyJul 2027
NCT06505395SYHX2008 injectionPhase 2Gastrointestinal Neuroendocrine Pancreatic TumorGastroenterologyAug 2027
NCT07093710MitoxantronePhase 1Peripheral T Cell LymphomaOncologyAug 2027
NCT06494150SirolimusPhase 2Low Grade Ovarian Serous AdenocarcinomaOncologyAug 2027
NCT06486337MitoxantronePhase 2NHLOncologyAug 2027
NCT07131644SirolimusPhase 2Kaposiform HemangioendotheliomaOncologySep 2027
NCT06727305SirolimusPhase 1AgingOtherSep 2027
NCT07262957OctreotidePhase 4Pancreas Head CancerOncologySep 2027
NCT02042326SirolimusPhase 2Arteriovenous MalformationsOtherSep 2027

The 60 nearest readouts of 118 trials; the rest in the app.

Targets

SLC6A3 (1) FKBP1A (1) TOP2A (1) MAP2K1 (1) SSTR5 (1) SSTR2 (1) SSTR4 (1) SSTR1 (1) SSTR3 (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA RayzeBio Axsome Therapeutics Roche ITM Solucin Advanced Accelerator Applications RECORDATI GROUP Debiopharm International

Companies built like this

Merck KGaA Ono Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai Henlius Biotech Mabwell (Shanghai) Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.